Ropes & Gray Advised Sanofi On The Acquisition Of Dren Bio’s Bispecific Antibody-Based Program In Immunology Deal Worth Up To USD 1.9 Billion

Ropes & Gray advised Sanofi on the acquisition of Dren Bio’s bispecific antibody-based program in immunology deal worth up to USD 1.9 billion

Ropes & Gray LLP advised Sanofi on its agreement to acquire Dren Bio’s deep B-cell depleter program, DR-0201, through the acquisition of Dren Bio affiliate Dren-0201.

DR-0201, a targeted bispecific myeloid cell engager, has the potential to reset the adaptive immune system and could lead to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, addressing significant unmet medical needs.

Under the terms of the agreement, Sanofi will make an upfront payment of USD 600 million, with potential additional payments of up to USD 1.3 billion contingent on the achievement of development and launch milestones. The transaction is expected to close in Q2 2025.

The Ropes & Gray team was led by Abigail Gregor, Life Sciences Licensing Partner; Matthew J. Byron, M&A Partner; and Daniel Freshman, IP Transactions Associate. The team also included Scott J. Pinarchick, Tax Partner; Renata J. Ferrari, Employment & Benefits Partner; Joshua Talicska, IP Transactions Counsel; Alexandra Charron, M&A Associate; and Giancarlo Lee, IP Transactions Associate.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.